Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Feb;12(1):79-82.
doi: 10.1007/s10048-010-0254-5. Epub 2010 Aug 1.

OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users

Matthijs L Becker  1 , Loes E Visser, Ron H N van Schaik, Albert Hofman, André G Uitterlinden, Bruno H Ch Stricker
Affiliations

OCT1 polymorphism is associated with response and survival time in anti-Parkinsonian drug users

Matthijs L Becker et al. Neurogenetics. 2011 Feb.

Abstract

Substrates for the Organic Cation Transporter 1, encoded by the SLC22A1 gene, are metformin, amantadine, pramipexole, and, possibly, levodopa. Recently, we identified that the rs622342 A > C polymorphism is associated with the HbA1c lowering effect in metformin users. In the Rotterdam Study, we associated this polymorphism with higher prescribed doses of all anti-Parkinsonian drugs. Between the first and fifth prescriptions for levodopa, for each minor rs622342 C allele, the prescribed doses were 0.34 defined daily dose higher (95% CI 0.064, 0.62; p=0.017). The mortality ratio after start of levodopa therapy was 1.47 times higher (95% CI 1.01, 2.13; p=0.045).

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Rs622342 genotype and change in prescribed doses of anti-Parkinsonian drugs (bars represent standard error)
See this image and copyright information in PMC

References

    1. Koepsell H, Lips K, Volk C. Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm Res. 2007;24:1227–1251. doi: 10.1007/s11095-007-9254-z. - DOI - PubMed
    1. Jonker JW, Schinkel AH. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3) J Pharmacol Exp Ther. 2004;308:2–9. doi: 10.1124/jpet.103.053298. - DOI - PubMed
    1. Breidert T, Spitzenberger F, Grundemann D, Schomig E. Catecholamine transport by the organic cation transporter type 1 (OCT1) Br J Pharmacol. 1998;125:218–224. doi: 10.1038/sj.bjp.0702065. - DOI - PMC - PubMed
    1. Okura T, Ito R, Ishiguro N, Tamai I, Deguchi Y. Blood-brain barrier transport of pramipexole, a dopamine D2 agonist. Life Sci. 2007;80:1564–1571. doi: 10.1016/j.lfs.2007.01.035. - DOI - PubMed
    1. Ishiguro N, Saito A, Yokoyama K, Morikawa M, Igarashi T, Tamai I. Transport of the dopamine D2 agonist pramipexole by rat organic cation transporters OCT1 and OCT2 in kidney. Drug Metab Dispos. 2005;33:495–499. doi: 10.1124/dmd.104.002519. - DOI - PubMed

Publication types

MeSH terms